![\"This](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/03\/alpha-synuclein-alzheimers-women-parkinsons-neuroscience.jpg\")
Research shows that alpha-synuclein significantly drives faster tau accumulation in women, offering a new explanation for the sex-disparity in Alzheimer\u2019s disease. Credit: Neuroscience News<\/p>\nSummary: Women make up nearly two-thirds of Alzheimer\u2019s patients, and researcher may have just discovered a massive reason why. A new study found that when the protein alpha-synuclein (typically associated with Parkinson\u2019s) clumps together alongside Alzheimer\u2019s pathology, brain changes in women progressed up to 20 times faster.<\/p>\n
Surprisingly, this \u201caccelerator\u201d effect was not seen in men. The discovery suggests that the interaction between tau and alpha-synuclein creates a unique, high-speed vulnerability in the female brain, potentially redefining how we screen for and treat Alzheimer\u2019s in women.<\/p>\n
Key Facts<\/p>\n
The 20X Factor: In women with both tau (Alzheimer\u2019s) and alpha-synuclein (Parkinson\u2019s) abnormalities, brain degeneration occurred 20 times faster than in those without the co-pathology.Sex-Specific Vulnerability: Men with the same protein clumping did not experience the same rapid acceleration, indicating a profound biological difference in how female brains handle \u201cmisfolded\u201d proteins.Alpha-Synuclein\u2019s Role: While primary to Parkinson\u2019s and Lewy Body dementia, this protein often appears as a \u201csilent passenger\u201d in Alzheimer\u2019s patients, significantly worsening the prognosis for women.Imaging Breakthrough: Mayo Clinic researchers used advanced brain imaging and cerebrospinal fluid testing from 415 participants to track these protein interactions over time.Precision Medicine: The findings highlight that Alzheimer\u2019s is not a \u201cone-size-fits-all\u201d disease and that women may require different screening for Lewy Body proteins to accurately predict their disease trajectory.<\/p>\n
Source: Mayo Clinic<\/p>\n
Alzheimer\u2019s-related brain changes progressed up to 20 times faster in women who also had abnormal levels of a Parkinson\u2019s-related protein, according to a\u00a0Mayo Clinic\u00a0study published in JAMA Network Open. The same pattern was not observed in men.<\/p>\n
The findings suggest that when alpha-synuclein \u2014 a protein linked to Parkinson\u2019s disease \u2014 accumulates alongside Alzheimer\u2019s pathology, it may drive faster disease progression in women. That interaction could help explain a long-standing disparity: women make up nearly\u00a0two-thirds\u00a0of people living with Alzheimer\u2019s disease in the U.S.<\/p>\n
Research shows that alpha-synuclein significantly drives faster tau accumulation in women, offering a new explanation for the sex-disparity in Alzheimer\u2019s disease. Credit: Neuroscience News<\/p>\n
Kejal Kantarci, M.D., a Mayo Clinic neuroradiologist and senior author of the study, uses advanced brain imaging to track Alzheimer\u2019s progression.<\/p>\n
\u201cRecognizing these sex-specific differences could help us design more targeted clinical trials and ultimately more personalized treatment strategies,\u201d Dr. Kantarci says.<\/p>\n
\u201cWhen we see disease-related changes unfolding at dramatically different rates, we cannot keep approaching Alzheimer\u2019s as though it behaves exactly the same way in everyone. Co-pathologies may impact the disease process.\u201d<\/p>\n
Alzheimer\u2019s disease is marked by the buildup of tau protein in the brain. Many people along the Alzheimer\u2019s disease continuum also develop abnormal clumping of\u00a0\u03b1-synuclein, a protein associated with Lewy body diseases such as Parkinson\u2019s disease and dementia with Lewy bodies.\u00a0<\/p>\n
Tau and\u00a0\u03b1-synuclein\u00a0occur\u00a0naturally in the brain. In neurodegenerative diseases, however,\u00a0these proteins\u00a0can misfold and clump\u00a0together, forming\u00a0abnormal deposits. This pathological\u00a0buildup disrupts\u00a0communication between brain cells and\u00a0contributes\u00a0to cognitive decline.\u00a0<\/p>\n
Researchers set out to determine whether having both abnormal protein buildups alters how the disease progresses and whether that effect differs between women and men.<\/p>\n
To investigate, the team analyzed data from 415 participants in the Alzheimer\u2019s Disease Neuroimaging Initiative, a national research consortium that tracks brain changes over time.<\/p>\n
Participants underwent cerebrospinal fluid testing to detect abnormal \u03b1-synuclein and repeated brain imaging to measure changes in tau accumulation. About 17% of participants showed evidence of abnormal \u03b1-synuclein.<\/p>\n
Among participants with both Alzheimer\u2019s-related pathology and \u03b1-synuclein abnormalities, women accumulated tau dramatically faster than men with the same coexisting protein changes.<\/p>\n
Elijah Mak, Ph.D., first author of the study and a Mayo Clinic neuroimaging researcher, studies how multiple brain pathologies interact and drive disease progression.<\/p>\n
\u201cThis opens an entirely new direction for understanding why women bear a disproportionate burden of dementia,\u201d Dr. Mak says. \u201cIf we can unravel the mechanisms behind this vulnerability, we may uncover targets we haven\u2019t considered before.\u201d<\/p>\n
The researchers are now examining whether these sex-specific effects also appear in patients with dementia with Lewy bodies, where \u03b1-synuclein is the primary disease driver rather than a coexisting pathology.<\/p>\n
The work will help determine whether the observed difference is unique to Alzheimer\u2019s disease or reflects a broader sex-specific vulnerability across neurodegenerative conditions.<\/p>\n
For a complete list of authors, disclosures and funding, review the study.<\/p>\n
Key Questions Answered:Q: Does having Parkinson\u2019s proteins mean I\u2019ll get Parkinson\u2019s and Alzheimer\u2019s?<\/p>\n
A: Not necessarily. These proteins can \u201cmisfold\u201d in the brain even if you don\u2019t have a full Parkinson\u2019s diagnosis. This study shows that when these proteins (alpha-synuclein) show up in an Alzheimer\u2019s brain, they act like fuel on a fire\u2014specifically in women\u2014speeding up the loss of brain function.<\/p>\n
Q: Why does this only affect women?<\/p>\n
A: This is the million-dollar question researchers are now racing to answer. It could be linked to hormonal differences, how the female immune system reacts to \u201cclumped\u201d proteins, or different wiring in the brain\u2019s waste-clearance systems. This discovery is the first step in unlocking that mystery.<\/p>\n
Q: Can we test for this \u201caccelerator\u201d protein?<\/p>\n
A: Yes. Doctors can use cerebrospinal fluid (CSF) tests to detect abnormal alpha-synuclein levels. This research suggests that for women, these tests could be crucial for determining how quickly the disease might progress and which clinical trials would be most effective.<\/p>\n
Editorial Notes:This article was edited by a Neuroscience News editor.Journal paper reviewed in full.Additional context added by our staff.About this Alzheimer\u2019s disease and Parkinson\u2019s disease research news<\/p>\n
Author: Emily DeBoom<\/a>
Source: Mayo Clinic<\/a>
Contact: Emily DeBoom \u2013 Mayo Clinic
Image: The image is credited to Neuroscience News<\/p>\n